✦ LIBER ✦

Brain metastases from epithelial ovarian carcinoma: Evaluation of prognosis and managements — A Taiwanese Gynecologic Oncology Group (TGOG) Study

✍ Scribed by Ying-Cheng Chiang; Jian-Tai Qiu; Chih-Long Chang; Peng-Hui Wang; Chih-Ming Ho; Wu-Chou Lin; Yu-Fang Huang; Hao Lin; Chien-Hsing Lu; Cheng-Yang Chou

Book ID: 113963992
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 282 KB
Volume: 125
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2011.12.438

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of management on the prognosis of

Impact of management on the prognosis of pure uterine papillary serous cancer — A Taiwanese Gynecologic Oncology Group (TGOG) study

✍ Huang, Chia-Yen; Tang, Yun-Hsin; Chiang, Ying-Cheng; Wang, Kung-Liahng; Fu, Hung 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 430 KB

Co-expression of angiogenic markers and

Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: A Gynecologic Oncology Group study

✍ Angeles Alvarez Secord; Kathleen M. Darcy; Alan Hutson; Paula S. Lee; Laura J. H 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 603 KB

Phase II evaluation of dasatinib in the

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Russell J. Schilder; William E. Brady; Heather A. Lankes; James V. Fiorica; Mark 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 205 KB

A phase II evaluation of lapatinib in th

A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study

✍ Agustin A. Garcia; Michael W. Sill; Heather A. Lankes; Andrew K. Godwin; Robert 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 220 KB

Phase II evaluation of three-day topotec

Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma : A Gynecologic Oncology Group study

✍ David Scott Miller; John A. Blessing; Samuel S. Lentz; D. Scott McMeekin 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract ## BACKGROUND Topotecan, administeredintravenously at a dose of 1.5 mg/m^2^ per day for 5 days every 21 days, is an established regimen in the treatment of recurrent ovarian carcinoma. Alternate dosing strategies have sought to improve toxicity. The authors evaluated the tolerability a

A phase II evaluation of AMG 102 (rilotu

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Martin, Lainie P.; Sill, Michael; Shahin, Mark S.; Powell, Matthew; DiSilvestro, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 246 KB